Gene panel sequencing of colorectal cancer patients

This study involves targeted next-generation sequencing (NGS) of tumor and/or matched normal samples from colorectal cancer (CRC) patients, using a custom-designed gene panel. The panel includes a curated set of cancer-related genes known to be frequently mutated in colorectal cancer, including both oncogenes and tumor suppressor genes such as APC, TP53, KRAS, NRAS, BRAF, PIK3CA, SMAD4, PTEN, and others implicated in key signaling pathways (WNT, MAPK, PI3K-AKT). Samples were collected from histologically confirmed CRC patients following appropriate ethical approvals and informed consent. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissues and/or peripheral blood samples. Libraries were prepared using hybridization-based capture protocols, followed by sequencing on an Illumina platform. Sequencing data was generated at high depth (typically >500×) to ensure sensitive detection of somatic mutations, copy number alterations, and microsatellite instability (MSI) signatures where applicable. The objectives of this study are: To characterize the mutational landscape of colorectal cancer in our cohort To identify clinically actionable variants To explore tumor heterogeneity and potential biomarkers of prognosis and therapeutic response